Apricus Biosciences announced that Bassam Damaj, Ph.D., has resigned as a director, president, and CEO of the company and that Steve Martin, senior vice president and CFO, has been appointed interim CEO. The changes are effective immediately. The company also announced that its board has retained an executive recruiting firm to assist in identifying a permanent CEO whose experience is expected to include significant background in commercial operations within the pharmaceutical industry.
- Board & Management Changes
- Investment & Company Information
- Apricus Biosciences
- Steve Martin
- senior vice president